Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
April 2, 2018 6:51 AM EDT
UBS initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $18.00.
For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.
Shares of BioXcel Therapeutics closed at $10.24 Friday.
...
More
April 2, 2018 4:26 AM EDT
Barclays initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Overweight rating and a price target of $15.00.
Analyst Geoff Meacham says the company is a unique play in both neurology and oncology as well as AI and sees good potential for shares... More
April 2, 2018 4:23 AM EDT
BMO Capital initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Outperform rating and a price target of $23.00.
Analyst Do Kim comments "We believe BXCL501's sublingual formulation and favorable efficacy/safety profile will enable BioXcel to consolidate a highly fragmented market in... More
